カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のブピバカインリポソーム注射用懸濁液市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Bupivacaine Liposome Injectable Suspension Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19200）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19200
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：78
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のブピバカインリポソーム注射用懸濁液市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

ブピバカインリポソーム注射用懸濁液市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のブピバカインリポソーム注射用懸濁液の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

ブピバカインリポソーム注射用懸濁液市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・20ml、10ml

用途別セグメントは次のように区分されます。
・獣医学、ヒト

世界のブピバカインリポソーム注射用懸濁液市場の主要な市場プレーヤーは以下のとおりです。
・Pacira Pharmaceuticals

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、ブピバカインリポソーム注射用懸濁液製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なブピバカインリポソーム注射用懸濁液メーカーの企業概要、2019年～2022年までのブピバカインリポソーム注射用懸濁液の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なブピバカインリポソーム注射用懸濁液メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別ブピバカインリポソーム注射用懸濁液の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのブピバカインリポソーム注射用懸濁液の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのブピバカインリポソーム注射用懸濁液市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびブピバカインリポソーム注射用懸濁液の産業チェーンを掲載しています。
・第13、14、15章では、ブピバカインリポソーム注射用懸濁液の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- ブピバカインリポソーム注射用懸濁液の概要
- 種類別分析（2017年vs2021年vs2028年）：20ml、10ml
- 用途別分析（2017年vs2021年vs2028年）：獣医学、ヒト
- 世界のブピバカインリポソーム注射用懸濁液市場規模・予測
- 世界のブピバカインリポソーム注射用懸濁液生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Pacira Pharmaceuticals
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：20ml、10ml
・用途別分析2017年-2028年：獣医学、ヒト
・ブピバカインリポソーム注射用懸濁液の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・ブピバカインリポソーム注射用懸濁液のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・ブピバカインリポソーム注射用懸濁液のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・ブピバカインリポソーム注射用懸濁液の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・ブピバカインリポソーム注射用懸濁液の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Bupivacaine Liposome Injectable Suspension market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Bupivacaine Liposome Injectable Suspension market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Veterinary accounting for % of the Bupivacaine Liposome Injectable Suspension global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 20ml segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Bupivacaine Liposome Injectable Suspension include Pacira Pharmaceuticals, , , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Bupivacaine Liposome Injectable Suspension market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
20ml
10ml
Market segment by Application can be divided into
Veterinary
Human
The key market players for global Bupivacaine Liposome Injectable Suspension market are listed below:
Pacira Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bupivacaine Liposome Injectable Suspension product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Bupivacaine Liposome Injectable Suspension, with price, sales, revenue and global market share of Bupivacaine Liposome Injectable Suspension from 2019 to 2022.
Chapter 3, the Bupivacaine Liposome Injectable Suspension competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bupivacaine Liposome Injectable Suspension breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Bupivacaine Liposome Injectable Suspension market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Bupivacaine Liposome Injectable Suspension.
Chapter 13, 14, and 15, to describe Bupivacaine Liposome Injectable Suspension sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Bupivacaine Liposome Injectable Suspension Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Bupivacaine Liposome Injectable Suspension Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 20ml
1.2.3 10ml
1.3 Market Analysis by Application
1.3.1 Overview: Global Bupivacaine Liposome Injectable Suspension Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Veterinary
1.3.3 Human
1.4 Global Bupivacaine Liposome Injectable Suspension Market Size & Forecast
1.4.1 Global Bupivacaine Liposome Injectable Suspension Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Bupivacaine Liposome Injectable Suspension Sales in Volume (2017-2028)
1.4.3 Global Bupivacaine Liposome Injectable Suspension Price (2017-2028)
1.5 Global Bupivacaine Liposome Injectable Suspension Production Capacity Analysis
1.5.1 Global Bupivacaine Liposome Injectable Suspension Total Production Capacity (2017-2028)
1.5.2 Global Bupivacaine Liposome Injectable Suspension Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Bupivacaine Liposome Injectable Suspension Market Drivers
1.6.2 Bupivacaine Liposome Injectable Suspension Market Restraints
1.6.3 Bupivacaine Liposome Injectable Suspension Trends Analysis
2 Manufacturers Profiles
2.1 Pacira Pharmaceuticals
2.1.1 Pacira Pharmaceuticals Details
2.1.2 Pacira Pharmaceuticals Major Business
2.1.3 Pacira Pharmaceuticals Bupivacaine Liposome Injectable Suspension Product and Services
2.1.4 Pacira Pharmaceuticals Bupivacaine Liposome Injectable Suspension Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Bupivacaine Liposome Injectable Suspension Breakdown Data by Manufacturer
3.1 Global Bupivacaine Liposome Injectable Suspension Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Bupivacaine Liposome Injectable Suspension Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Bupivacaine Liposome Injectable Suspension
3.4 Market Concentration Rate
3.4.1 Top 3 Bupivacaine Liposome Injectable Suspension Manufacturer Market Share in 2021
3.4.2 Top 6 Bupivacaine Liposome Injectable Suspension Manufacturer Market Share in 2021
3.5 Global Bupivacaine Liposome Injectable Suspension Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Bupivacaine Liposome Injectable Suspension Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Bupivacaine Liposome Injectable Suspension Market Size by Region
4.1.1 Global Bupivacaine Liposome Injectable Suspension Sales in Volume by Region (2017-2028)
4.1.2 Global Bupivacaine Liposome Injectable Suspension Revenue by Region (2017-2028)
4.2 North America Bupivacaine Liposome Injectable Suspension Revenue (2017-2028)
4.3 Europe Bupivacaine Liposome Injectable Suspension Revenue (2017-2028)
4.4 Asia-Pacific Bupivacaine Liposome Injectable Suspension Revenue (2017-2028)
4.5 South America Bupivacaine Liposome Injectable Suspension Revenue (2017-2028)
4.6 Middle East and Africa Bupivacaine Liposome Injectable Suspension Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Bupivacaine Liposome Injectable Suspension Sales in Volume by Type (2017-2028)
5.2 Global Bupivacaine Liposome Injectable Suspension Revenue by Type (2017-2028)
5.3 Global Bupivacaine Liposome Injectable Suspension Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Bupivacaine Liposome Injectable Suspension Sales in Volume by Application (2017-2028)
6.2 Global Bupivacaine Liposome Injectable Suspension Revenue by Application (2017-2028)
6.3 Global Bupivacaine Liposome Injectable Suspension Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2028)
7.2 North America Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2028)
7.3 North America Bupivacaine Liposome Injectable Suspension Market Size by Country
7.3.1 North America Bupivacaine Liposome Injectable Suspension Sales in Volume by Country (2017-2028)
7.3.2 North America Bupivacaine Liposome Injectable Suspension Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2028)
8.2 Europe Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2028)
8.3 Europe Bupivacaine Liposome Injectable Suspension Market Size by Country
8.3.1 Europe Bupivacaine Liposome Injectable Suspension Sales in Volume by Country (2017-2028)
8.3.2 Europe Bupivacaine Liposome Injectable Suspension Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2028)
9.2 Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2028)
9.3 Asia-Pacific Bupivacaine Liposome Injectable Suspension Market Size by Region
9.3.1 Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Bupivacaine Liposome Injectable Suspension Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2028)
10.2 South America Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2028)
10.3 South America Bupivacaine Liposome Injectable Suspension Market Size by Country
10.3.1 South America Bupivacaine Liposome Injectable Suspension Sales in Volume by Country (2017-2028)
10.3.2 South America Bupivacaine Liposome Injectable Suspension Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2028)
11.2 Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2028)
11.3 Middle East & Africa Bupivacaine Liposome Injectable Suspension Market Size by Country
11.3.1 Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Bupivacaine Liposome Injectable Suspension Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Bupivacaine Liposome Injectable Suspension and Key Manufacturers
12.2 Manufacturing Costs Percentage of Bupivacaine Liposome Injectable Suspension
12.3 Bupivacaine Liposome Injectable Suspension Production Process
12.4 Bupivacaine Liposome Injectable Suspension Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Bupivacaine Liposome Injectable Suspension Typical Distributors
13.3 Bupivacaine Liposome Injectable Suspension Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Bupivacaine Liposome Injectable Suspension Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Bupivacaine Liposome Injectable Suspension Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Pacira Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Pacira Pharmaceuticals Major Business
Table 5. Pacira Pharmaceuticals Bupivacaine Liposome Injectable Suspension Product and Services
Table 6. Pacira Pharmaceuticals Bupivacaine Liposome Injectable Suspension Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Global Bupivacaine Liposome Injectable Suspension Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 8. Global Bupivacaine Liposome Injectable Suspension Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 9. Market Position of Manufacturers in Bupivacaine Liposome Injectable Suspension, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 10. Global Bupivacaine Liposome Injectable Suspension Production Capacity by Company, (K Units): 2020 VS 2021
Table 11. Head Office and Bupivacaine Liposome Injectable Suspension Production Site of Key Manufacturer
Table 12. Bupivacaine Liposome Injectable Suspension New Entrant and Capacity Expansion Plans
Table 13. Bupivacaine Liposome Injectable Suspension Mergers & Acquisitions in the Past Five Years
Table 14. Global Bupivacaine Liposome Injectable Suspension Sales by Region (2017-2022) & (K Units)
Table 15. Global Bupivacaine Liposome Injectable Suspension Sales by Region (2023-2028) & (K Units)
Table 16. Global Bupivacaine Liposome Injectable Suspension Revenue by Region (2017-2022) & (USD Million)
Table 17. Global Bupivacaine Liposome Injectable Suspension Revenue by Region (2023-2028) & (USD Million)
Table 18. Global Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2022) & (K Units)
Table 19. Global Bupivacaine Liposome Injectable Suspension Sales by Type (2023-2028) & (K Units)
Table 20. Global Bupivacaine Liposome Injectable Suspension Revenue by Type (2017-2022) & (USD Million)
Table 21. Global Bupivacaine Liposome Injectable Suspension Revenue by Type (2023-2028) & (USD Million)
Table 22. Global Bupivacaine Liposome Injectable Suspension Price by Type (2017-2022) & (US$/Unit)
Table 23. Global Bupivacaine Liposome Injectable Suspension Price by Type (2023-2028) & (US$/Unit)
Table 24. Global Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2022) & (K Units)
Table 25. Global Bupivacaine Liposome Injectable Suspension Sales by Application (2023-2028) & (K Units)
Table 26. Global Bupivacaine Liposome Injectable Suspension Revenue by Application (2017-2022) & (USD Million)
Table 27. Global Bupivacaine Liposome Injectable Suspension Revenue by Application (2023-2028) & (USD Million)
Table 28. Global Bupivacaine Liposome Injectable Suspension Price by Application (2017-2022) & (US$/Unit)
Table 29. Global Bupivacaine Liposome Injectable Suspension Price by Application (2023-2028) & (US$/Unit)
Table 30. North America Bupivacaine Liposome Injectable Suspension Sales by Country (2017-2022) & (K Units)
Table 31. North America Bupivacaine Liposome Injectable Suspension Sales by Country (2023-2028) & (K Units)
Table 32. North America Bupivacaine Liposome Injectable Suspension Revenue by Country (2017-2022) & (USD Million)
Table 33. North America Bupivacaine Liposome Injectable Suspension Revenue by Country (2023-2028) & (USD Million)
Table 34. North America Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2022) & (K Units)
Table 35. North America Bupivacaine Liposome Injectable Suspension Sales by Type (2023-2028) & (K Units)
Table 36. North America Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2022) & (K Units)
Table 37. North America Bupivacaine Liposome Injectable Suspension Sales by Application (2023-2028) & (K Units)
Table 38. Europe Bupivacaine Liposome Injectable Suspension Sales by Country (2017-2022) & (K Units)
Table 39. Europe Bupivacaine Liposome Injectable Suspension Sales by Country (2023-2028) & (K Units)
Table 40. Europe Bupivacaine Liposome Injectable Suspension Revenue by Country (2017-2022) & (USD Million)
Table 41. Europe Bupivacaine Liposome Injectable Suspension Revenue by Country (2023-2028) & (USD Million)
Table 42. Europe Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2022) & (K Units)
Table 43. Europe Bupivacaine Liposome Injectable Suspension Sales by Type (2023-2028) & (K Units)
Table 44. Europe Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2022) & (K Units)
Table 45. Europe Bupivacaine Liposome Injectable Suspension Sales by Application (2023-2028) & (K Units)
Table 46. Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales by Region (2017-2022) & (K Units)
Table 47. Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales by Region (2023-2028) & (K Units)
Table 48. Asia-Pacific Bupivacaine Liposome Injectable Suspension Revenue by Region (2017-2022) & (USD Million)
Table 49. Asia-Pacific Bupivacaine Liposome Injectable Suspension Revenue by Region (2023-2028) & (USD Million)
Table 50. Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2022) & (K Units)
Table 51. Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales by Type (2023-2028) & (K Units)
Table 52. Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2022) & (K Units)
Table 53. Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales by Application (2023-2028) & (K Units)
Table 54. South America Bupivacaine Liposome Injectable Suspension Sales by Country (2017-2022) & (K Units)
Table 55. South America Bupivacaine Liposome Injectable Suspension Sales by Country (2023-2028) & (K Units)
Table 56. South America Bupivacaine Liposome Injectable Suspension Revenue by Country (2017-2022) & (USD Million)
Table 57. South America Bupivacaine Liposome Injectable Suspension Revenue by Country (2023-2028) & (USD Million)
Table 58. South America Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2022) & (K Units)
Table 59. South America Bupivacaine Liposome Injectable Suspension Sales by Type (2023-2028) & (K Units)
Table 60. South America Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2022) & (K Units)
Table 61. South America Bupivacaine Liposome Injectable Suspension Sales by Application (2023-2028) & (K Units)
Table 62. Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales by Region (2017-2022) & (K Units)
Table 63. Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales by Region (2023-2028) & (K Units)
Table 64. Middle East & Africa Bupivacaine Liposome Injectable Suspension Revenue by Region (2017-2022) & (USD Million)
Table 65. Middle East & Africa Bupivacaine Liposome Injectable Suspension Revenue by Region (2023-2028) & (USD Million)
Table 66. Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales by Type (2017-2022) & (K Units)
Table 67. Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales by Type (2023-2028) & (K Units)
Table 68. Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales by Application (2017-2022) & (K Units)
Table 69. Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales by Application (2023-2028) & (K Units)
Table 70. Bupivacaine Liposome Injectable Suspension Raw Material
Table 71. Key Manufacturers of Bupivacaine Liposome Injectable Suspension Raw Materials
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Bupivacaine Liposome Injectable Suspension Typical Distributors
Table 75. Bupivacaine Liposome Injectable Suspension Typical Customers
List of Figures
Figure 1. Bupivacaine Liposome Injectable Suspension Picture
Figure 2. Global Bupivacaine Liposome Injectable Suspension Revenue Market Share by Type in 2021
Figure 3. 20ml
Figure 4. 10ml
Figure 5. Global Bupivacaine Liposome Injectable Suspension Revenue Market Share by Application in 2021
Figure 6. Veterinary
Figure 7. Human
Figure 8. Global Bupivacaine Liposome Injectable Suspension Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Bupivacaine Liposome Injectable Suspension Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Bupivacaine Liposome Injectable Suspension Sales (2017-2028) & (K Units)
Figure 11. Global Bupivacaine Liposome Injectable Suspension Price (2017-2028) & (US$/Unit)
Figure 12. Global Bupivacaine Liposome Injectable Suspension Production Capacity (2017-2028) & (K Units)
Figure 13. Global Bupivacaine Liposome Injectable Suspension Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Bupivacaine Liposome Injectable Suspension Market Drivers
Figure 15. Bupivacaine Liposome Injectable Suspension Market Restraints
Figure 16. Bupivacaine Liposome Injectable Suspension Market Trends
Figure 17. Global Bupivacaine Liposome Injectable Suspension Sales Market Share by Manufacturer in 2021
Figure 18. Global Bupivacaine Liposome Injectable Suspension Revenue Market Share by Manufacturer in 2021
Figure 19. Bupivacaine Liposome Injectable Suspension Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Bupivacaine Liposome Injectable Suspension Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Bupivacaine Liposome Injectable Suspension Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Bupivacaine Liposome Injectable Suspension Sales Market Share by Region (2017-2028)
Figure 23. Global Bupivacaine Liposome Injectable Suspension Revenue Market Share by Region (2017-2028)
Figure 24. North America Bupivacaine Liposome Injectable Suspension Revenue (2017-2028) & (USD Million)
Figure 25. Europe Bupivacaine Liposome Injectable Suspension Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Bupivacaine Liposome Injectable Suspension Revenue (2017-2028) & (USD Million)
Figure 27. South America Bupivacaine Liposome Injectable Suspension Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Bupivacaine Liposome Injectable Suspension Revenue (2017-2028) & (USD Million)
Figure 29. Global Bupivacaine Liposome Injectable Suspension Sales Market Share by Type (2017-2028)
Figure 30. Global Bupivacaine Liposome Injectable Suspension Revenue Market Share by Type (2017-2028)
Figure 31. Global Bupivacaine Liposome Injectable Suspension Price by Type (2017-2028) & (US$/Unit)
Figure 32. Global Bupivacaine Liposome Injectable Suspension Sales Market Share by Application (2017-2028)
Figure 33. Global Bupivacaine Liposome Injectable Suspension Revenue Market Share by Application (2017-2028)
Figure 34. Global Bupivacaine Liposome Injectable Suspension Price by Application (2017-2028) & (US$/Unit)
Figure 35. North America Bupivacaine Liposome Injectable Suspension Sales Market Share by Type (2017-2028)
Figure 36. North America Bupivacaine Liposome Injectable Suspension Sales Market Share by Application (2017-2028)
Figure 37. North America Bupivacaine Liposome Injectable Suspension Sales Market Share by Country (2017-2028)
Figure 38. North America Bupivacaine Liposome Injectable Suspension Revenue Market Share by Country (2017-2028)
Figure 39. United States Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Bupivacaine Liposome Injectable Suspension Sales Market Share by Type (2017-2028)
Figure 43. Europe Bupivacaine Liposome Injectable Suspension Sales Market Share by Application (2017-2028)
Figure 44. Europe Bupivacaine Liposome Injectable Suspension Sales Market Share by Country (2017-2028)
Figure 45. Europe Bupivacaine Liposome Injectable Suspension Revenue Market Share by Country (2017-2028)
Figure 46. Germany Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Bupivacaine Liposome Injectable Suspension Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Bupivacaine Liposome Injectable Suspension Revenue Market Share by Region (2017-2028)
Figure 55. China Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Bupivacaine Liposome Injectable Suspension Sales Market Share by Type (2017-2028)
Figure 62. South America Bupivacaine Liposome Injectable Suspension Sales Market Share by Application (2017-2028)
Figure 63. South America Bupivacaine Liposome Injectable Suspension Sales Market Share by Country (2017-2028)
Figure 64. South America Bupivacaine Liposome Injectable Suspension Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Bupivacaine Liposome Injectable Suspension Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Bupivacaine Liposome Injectable Suspension Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Bupivacaine Liposome Injectable Suspension Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Bupivacaine Liposome Injectable Suspension in 2021
Figure 76. Manufacturing Process Analysis of Bupivacaine Liposome Injectable Suspension
Figure 77. Bupivacaine Liposome Injectable Suspension Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のリポソームブピバカイン市場2022年：市場規模予測（～2028年）
  • 世界のビンクリスチン硫酸リポソーム注射市場2022年：市場規模予測（～2028年）
  • 世界の硫酸ビンクリスチン リポソーム注射剤市場2022年：市場規模予測（～2028年）
  • 世界のブピバカイン塩酸塩市場2022年：市場規模予測（～2028年）
  • 世界の注射用カルシウムハイドロキシルアパタイト市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19200 )"世界のブピバカインリポソーム注射用懸濁液市場2022年：市場規模予測（～2028年）" (英文：Global Bupivacaine Liposome Injectable Suspension Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。